Artwork

Contenuto fornito da Sonya Del Tredici and John Keenan, Sonya Del Tredici, and John Keenan. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da Sonya Del Tredici and John Keenan, Sonya Del Tredici, and John Keenan o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.
Player FM - App Podcast
Vai offline con l'app Player FM !

37. Injectable Vs. Sublingual Buprenorphine

46:46
 
Condividi
 

Manage episode 399348333 series 3378548
Contenuto fornito da Sonya Del Tredici and John Keenan, Sonya Del Tredici, and John Keenan. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da Sonya Del Tredici and John Keenan, Sonya Del Tredici, and John Keenan o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.

37. Injectable Vs. Sublingual Buprenorphine

In episode 37 we discuss an article comparing injectable and sublingual buprenorphine.

Superiority and cost-effectiveness of monthly extended-release buprenorphine versus daily standard of care medication: a pragmatic, parallel-group, open-label, multicentre, randomised, controlled, phase 3 trial. Marsden, John et al. eClinicalMedicine, Volume 66, 102311

We also discuss new data on the teratogenicity of fentanyl, and a new genetic test to identify the risk for opioid use disorder.

Genetics on Medicine Open: A novel syndrome associated with prenatal fentanyl exposure

FDA: FDA Approves First Test to Help Identify Elevated Risk of Developing Opioid Use Disorder

----------

This podcast offers category 1 and MATE-ACT CME credits through MI CARES and Michigan State University. To get credit for this episode and others, go to this link to make your account, take a brief quiz, and claim your credit. To learn more about opportunities in addiction medicine, please visit MI CARES.

----------

Episode 37 Credits:

----------

This is Addiction Medicine Journal Club with Dr. Sonya Del Tredici and Dr. John Keenan. We practice addiction medicine and primary care, and we believe that addiction is a disease that can be treated. This podcast reviews current articles to help you stay up to date with research that you can use in your addiction medicine practice.

The best part of any journal club is the conversation. Send us your comments on social media or join our Facebook group.

Addiction Medicine Journal Club is intended for educational purposes only and should not be considered medical advice. The views expressed here are our own and do not necessarily reflect those of our employers or the authors of the articles we review. All patient information has been modified to protect their identities.

  continue reading

47 episodi

Artwork
iconCondividi
 
Manage episode 399348333 series 3378548
Contenuto fornito da Sonya Del Tredici and John Keenan, Sonya Del Tredici, and John Keenan. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da Sonya Del Tredici and John Keenan, Sonya Del Tredici, and John Keenan o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.

37. Injectable Vs. Sublingual Buprenorphine

In episode 37 we discuss an article comparing injectable and sublingual buprenorphine.

Superiority and cost-effectiveness of monthly extended-release buprenorphine versus daily standard of care medication: a pragmatic, parallel-group, open-label, multicentre, randomised, controlled, phase 3 trial. Marsden, John et al. eClinicalMedicine, Volume 66, 102311

We also discuss new data on the teratogenicity of fentanyl, and a new genetic test to identify the risk for opioid use disorder.

Genetics on Medicine Open: A novel syndrome associated with prenatal fentanyl exposure

FDA: FDA Approves First Test to Help Identify Elevated Risk of Developing Opioid Use Disorder

----------

This podcast offers category 1 and MATE-ACT CME credits through MI CARES and Michigan State University. To get credit for this episode and others, go to this link to make your account, take a brief quiz, and claim your credit. To learn more about opportunities in addiction medicine, please visit MI CARES.

----------

Episode 37 Credits:

----------

This is Addiction Medicine Journal Club with Dr. Sonya Del Tredici and Dr. John Keenan. We practice addiction medicine and primary care, and we believe that addiction is a disease that can be treated. This podcast reviews current articles to help you stay up to date with research that you can use in your addiction medicine practice.

The best part of any journal club is the conversation. Send us your comments on social media or join our Facebook group.

Addiction Medicine Journal Club is intended for educational purposes only and should not be considered medical advice. The views expressed here are our own and do not necessarily reflect those of our employers or the authors of the articles we review. All patient information has been modified to protect their identities.

  continue reading

47 episodi

Tutti gli episodi

×
 
Loading …

Benvenuto su Player FM!

Player FM ricerca sul web podcast di alta qualità che tu possa goderti adesso. È la migliore app di podcast e funziona su Android, iPhone e web. Registrati per sincronizzare le iscrizioni su tutti i tuoi dispositivi.

 

Guida rapida